ProMIS Neurosciences Q4 EPS $(0.09) Beats $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
ProMIS Neurosciences (NASDAQ:PMN) reported Q4 losses of $(0.09) per share, surpassing the analyst consensus estimate of $(0.17) by 47.06%. This represents a significant improvement from the $(0.90) per share loss reported in the same quarter last year.
April 02, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProMIS Neurosciences reported a smaller Q4 loss than expected and showed significant improvement compared to last year.
Beating the EPS estimate by a significant margin and showing a substantial year-over-year improvement in earnings per share is likely to be viewed positively by investors. This could lead to increased investor confidence and potentially a short-term uptick in PMN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100